Dual Antithrombotic Therapy Targeting Residual Risk for Atherosclerotic Cardiovascular Disease: Does Body Mass Index Matter?

Karlyn Martin*, Sadiya S. Khan

*Corresponding author for this work

Research output: Contribution to journalEditorialpeer-review

Original languageEnglish (US)
Pages (from-to)526-528
Number of pages3
JournalJournal of the American College of Cardiology
Volume77
Issue number5
DOIs
StatePublished - Feb 9 2021

Keywords

  • DOAC
  • anticoagulant
  • cardiovascular risk
  • obesity
  • prevention
  • rivaroxaban

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this